AstraZeneca Plc AZN released updated exploratory results from the TOPAZ-1 Phase 3 trial of Imfinzi (durvalumab) in combination with standard-of-care chemotherapy for advanced biliary tract cancer (BTC).
The data showed that Imfinzi plus standard-of-care chemotherapy demonstrated a clinically meaningful long-term overall survival (OS) benefit in advanced biliary tract cancer patients at three years.
The company says the TOPAZ-1 results are the longest survival follow-up ever reported for a global, randomized Phase 3 trial in this setting.
Related: New Hope for Aggressive Lung Cancer: AstraZeneca’s Imfinzi Shows Promising Results in Phase 3 Trial.
At more than three years (median follow-up of 41.3 months), results showed that Imfinzi plus chemotherapy reduced the risk of death by 26% versus chemotherapy alone.
The median OS was 12.9 months for Imfinzi plus chemotherapy versus 11.3 months for chemotherapy alone.
More than twice as many patients on the Imfinzi-based regimen were alive at three years versus chemotherapy alone (14.6% versus 6.9%).
Do-Youn Oh, principal investigator in the trial, said: “The latest data from TOPAZ-1 show that twice as many patients with advanced biliary tract cancer were still alive at three years with durvalumab and chemotherapy, an especially meaningful advance in a setting where historically the prognosis has been poor.”
The TOPAZ-1 trial met the primary endpoint of OS in October 2021 at a planned interim analysis, showing that the combination reduced the risk of death by 20% versus chemotherapy alone.
Median OS was 12.8 months versus 11.5 for chemotherapy. An estimated 25% of patients were still alive at two years versus 10% for chemotherapy.
Results also showed a 25% reduction in the risk of disease progression or death with Imfinzi plus chemotherapy.
Median progression-free survival (PFS) was 7.2 months for the combination versus 5.7 for chemotherapy.
Patients treated with Imfinzi plus chemotherapy achieved an objective response rate (ORR) of 26.7% versus an ORR of 18.7% for patients treated with chemotherapy alone.
Read Next: AstraZeneca Hikes Annual Dividend By 7% Just Before Vote On Its CEO’s Pay Package Boost.
Price Action: AZN shares are down 0.01% at $68.72 during the premarket session on the last check Tuesday.
Photo via Wikimedia Commons
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
